Do Not Use Routine Low-Dose Aspirin for Primary Prevention in Patients ≥70 Years Without Known ASCVD
Based on the ASPREE trial and current guidelines, routine low-dose aspirin should NOT be used for primary prevention in patients aged 70 or older without atherosclerotic cardiovascular disease—the harms outweigh any potential benefits. 1, 2, 3
The Evidence Against Aspirin in This Population
The ASPREE trial specifically addressed this question in over 19,000 adults aged ≥65 years (including 56% women, median age 74 years). After a median follow-up of 4.7 years:
- No cardiovascular benefit: Aspirin showed no reduction in cardiovascular events (10.7 vs 11.3 events per 1,000 person-years; HR 0.95% CI 0.83-1.08) 1, 2
- Increased bleeding risk: Major hemorrhage occurred significantly more frequently with aspirin (8.6 vs 6.2 events per 1,000 person-years; HR 1.38,95% CI 1.18-1.62; P<0.001) 1, 2
- Increased mortality: There was an unexpected increased risk of death in the aspirin group 1
Current Guideline Recommendations
The 2019 ACC/AHA Primary Prevention Guidelines provide clear direction 3:
- Class III: Harm recommendation (Level of Evidence B-R): Low-dose aspirin (75-100 mg daily) should NOT be administered routinely for primary prevention in adults >70 years of age
- The number needed to treat to cause major bleeding (210) is actually LOWER than the number needed to prevent an ASCVD event (265), indicating more harm than benefit 1
The 2019 ADA Diabetes Guidelines reinforce this, stating: "For patients over the age of 70 years (with or without diabetes), the balance appears to have greater risk than benefit" 2
The 2024 AHA/ASA Stroke Prevention Guidelines also recommend against aspirin in this population (Class 3: No Benefit, Level A) 4
Why Older Adults Are Different
Several factors make aspirin particularly problematic in patients ≥70 years:
- Higher baseline bleeding risk: Older age itself increases bleeding risk from aspirin, particularly intracranial and gastrointestinal hemorrhage 1, 5
- Competing risks: Life expectancy and competing causes of mortality reduce the potential for long-term cardiovascular benefit
- Modern preventive therapy: Contemporary trials (ASPREE, ARRIVE, ASCEND) show less benefit than older trials because patients now receive better standard preventive care including statins and blood pressure control 1
Clinical Decision-Making Algorithm
For a patient ≥70 years without known ASCVD:
Step 1: Confirm no history of MI, stroke, or other established ASCVD
- If ASCVD present → Aspirin IS indicated for secondary prevention 2
Step 2: Assess bleeding risk factors:
- History of GI bleeding or peptic ulcer disease
- Thrombocytopenia or coagulopathy
- Chronic kidney disease
- Concurrent anticoagulants, NSAIDs, or steroids
- Uncontrolled hypertension
Step 3: For primary prevention in patients ≥70 years:
- Do NOT initiate aspirin regardless of ASCVD risk score 3, 4
- Focus on proven interventions: statin therapy, blood pressure control, smoking cessation, lifestyle modification
Step 4: If patient is already on aspirin for unclear reasons:
- Consider deprescribing, especially if bleeding risk factors present
- Discuss risks vs. benefits with shared decision-making
Common Pitfalls to Avoid
Don't use ASCVD risk calculators to justify aspirin in this age group: Even with high calculated risk, the bleeding risk outweighs benefit 2
Don't confuse primary and secondary prevention: Aspirin remains strongly indicated for secondary prevention (patients WITH known ASCVD) at any age 2, 6
Don't assume diabetes changes the recommendation: The ASCEND trial showed that even in diabetic patients, aspirin benefits were counterbalanced by bleeding risk, and age >70 years still represents greater risk than benefit 2
Don't continue aspirin "just in case": If started inappropriately, aspirin should be discontinued unless there's a clear secondary prevention indication
The Rare Exception
The only scenario where aspirin MIGHT be considered in select patients aged 40-70 years (not >70) is when ALL of the following apply 3:
- Very high ASCVD risk (>10% 10-year risk)
- Low bleeding risk
- Patient preference after shared decision-making
- Age 40-70 years (Class IIb recommendation)
This exception does NOT apply to patients ≥70 years, where the recommendation is Class III: Harm 3, 7, 4